Provided are polypeptides and compositions comprising the polypeptides for use in killing and/or inhibiting growth of Gram-negative bacteria, particularly P. aeruginosa. The polypeptides are contiguous polypeptides (lysocins) that contain an engineered bacteriocin segment that can be translocated through an outer membrane channel of the Gram-negative bacteria, such as Domain I of the S-type poycin from P. aeruginosa bacterocin pyocin S2 (PyS2) linked to a lysin catalytic segment that has peptidoglycan (PG) hydrolase activity. The lysin catalytic segment can be a catalytic segment of GN4 lysin or any other lysin catalytic segment or a hydrolytic enzyme thereof that has PG hydrolase activity.

The present invention relates to a bacteriophage-derived recombinant protein having antimicrobial activity against gram-negative bacteria, and the bacteriophage-derived recombinant protein LysSS exhibits killing activity to gram-negative bacteria and thus can prevent or treat infectious diseases caused by bacteria, and can be widely used in antibiotics, disinfectants, food additives, feed additives, and the like, wherein the LysSS uses peptidoglycan, which is a component of the cell wall of bacteria, as a substrate, and exhibits bacterial killing ability due to peptidoglycan degradation and the peptidoglycan exists only in bacteria and not in humans or animals.

The present disclosure is directed to lysin-AMP polypeptide constructs, isolated lysin polypeptides, and pharmaceutical compositions comprising the isolated polypeptides and/or lysin-AMP polypeptide constructs. Methods of using the lysin-AMP polypeptide constructs, isolated lysin polypeptides and pharmaceutical compositions are also herein provided, including methods of treating a bacterial infection of an organ or tissue in which pulmonary surfactant is present or Gram-negative bacterial infections that are associated with a biofilm. In addition, isolated polynucleotides encoding the lysin-AMP polypeptide constructs and isolated lysin polypeptides are disclosed herein.

The present description relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. Aureus and VISA.

The present invention generally relates to the use of a bifunctional peptidoglycan/chitin hydrolase to reduce and/or prevent hyphae formation in a pathogen, and/or to reduce or prevent biofilm formation. The present invention further relates to a bifunctional peptidoglycan/chitin hydrolase for use in the treatment and/or prevention of pathogenic infections, in particular yeast or bacterial infections. In another aspect, the present invention provides the use of a bifunctional peptidoglycan/chitin hydrolase as a anti-pathogenic agent in non-medical applications; in particular in the personal hygiene industry, food industry, cleaning industry, pharma industry, or biocontrol and crop protection industry.

Provided is a carrier which has excellent pressure resistance, and even when a protein ligand is not immobilized thereon, has a high dynamic binding capacity to a target substance, and has a high performance of separating a target substance from a biological sample.

The carrier includes a polymer having a crosslinked structure containing a divalent group represented by the following Formula (1):

##STR00001## wherein R.sup.1 to R.sup.4 independently represent a single bond or a divalent hydrocarbon group, R.sup.5 and R.sup.6 independently represent a hydrogen atom or a hydrocarbon group, X represents a thio group, a sulfinyl group, a sulfonyl group, an oxy group, >N(—R.sup.31), >Si(—R.sup.32).sub.2, >P(—R.sup.33), >P(═O)(—R.sup.34), >B(—R.sup.35), or >C(—R.sup.36).sub.2 (R.sup.31 to R.sup.36 independently represent a hydrogen atom or hydrocarbon group), and * represents a bond, with a proviso that when both R.sup.1 and R.sup.3 are a divalent hydrocarbon group, R.sup.1 and R.sup.3 may form a ring together with an adjacent carbon atom, and when both R.sup.2 and R.sup.4 are a divalent hydrocarbon group, R.sup.2 and R.sup.4 may form a ring together with an adjacent carbon atom.

Various aspects described herein relate to electrochemical devices, e.g., for separation of one or more biomolecules from a solution, and methods of using the same. Methods for using the electrochemical devices for biocatalysis are also described herein.

Provided is a norovirus deactivator, including a lysozyme component that includes at least one kind selected from lysozyme and/or a salt thereof, and a denatured product thereof.

The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to polypeptides comprising the sequence of a peptidoglycan hydrolase and a peptide sequence heterologous to the peptidoglycan hydrolase wherein said heterologous peptide sequence comprises a specific sequence motif which is 16, 17, 18, 19 or 20 amino acids in length. The present invention relates also to corresponding nucleic acids, vectors, bacteriophages, host cells, compositions and kits. The present inventions also relates to the use of said polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits in methods for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body. The polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits according to the invention may also be used as an antimicrobial in, e.g., food or feed, in cosmetics, or as disinfecting agent.

This document relates to conjugates of a biologically active molecule or a derivative thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.